Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents

Arthritis Care and Research

Volumn 64, Issue 9, 2012, Pages 1357-1364

  Nordstrom, Beth L ^a   Mines, Daniel ^b,c   Gu, Yun ^b,d   Mercaldi, Catherine ^a   Aquino, Peter ^b,d   Harrison, Melanie J ^b,d  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b PFIZER INC   (United States)

^c HEALTHCORE INC   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CORTICOSTEROID; METHOTREXATE;

ADOLESCENT; ARTICLE; BONE CANCER; BRAIN CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CHILD; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GINGIVA TUMOR; HUMAN; INFANT; JUVENILE RHEUMATOID ARTHRITIS; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOME ASSESSMENT; POPULATION; PRESCHOOL CHILD; SCHOOL CHILD; SKIN CANCER; SOFT TISSUE TUMOR; TENDON SHEATH; THYROID CANCER; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; MALE; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; YOUNG ADULT;

EID: 84865598635     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21709     Document Type: Article

References (18)

1. Manners PJ, Bower C,. Worldwide prevalence of juvenile arthritis: why does it vary so much? J Rheumatol 2002; 29: 1520-30.
2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
3. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63: 465-82.
4. Smitten AL, Simon TA, Hochberg MC, Suissa S,. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10: R45.
5. Food and Drug Administration. Early communication about an ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, and Cimzia). URL: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm070725.htm.
6. Food and Drug Administration. Follow-up to the June 4, 2008 early communication about the ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm174449.htm?utm-campaign= Google2&utm-source=fdaSearch&utm-medium=website&utm-term= follow-uptothejune4,2008early&utm-content=1.
7. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA registry. Ann Rheum Dis 2009; 68: 519-25.
8. McCroskery P, Wallace CA, Lovell DJ, Stryker S, Chernyukhin N, Blosch C, et al. Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J 2010; 8: 18.
9. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A,. Tumor necrosis factor α blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010; 62: 2517-24.
10. Wolfe F,. Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkin's lymphoma in rheumatoid arthritis: a 25-year study of 1,767 RA patients [abstract]. Arthritis Rheum 1998; 41 Suppl: S188.
11. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692-701.
12. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1414-20.
13. Simard JF, Neovius M, Hagelberg S, Askling J,. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010; 62: 3776-82.
14. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH,. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996; 32A: 1753-7.
15. Thomas E, Brewster DH, Black RJ, Macfarlane GJ,. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000; 88: 497-502.
16. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810-20.
17. Papsdorf V, Horneff G,. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford) 2011; 50: 214-21.
18. Visvanathan S, Wagner C, Marini JC, Lovell DJ, Martini A, Petty R, et al. The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatr Rheumatol Online J 2010; 8: 24.